152 related articles for article (PubMed ID: 19740389)
41. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
[TBL] [Abstract][Full Text] [Related]
42. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Chuk MK; Aikin A; Whitcomb T; Widemann BC; Zannikos P; Bayever E; Balis FM; Fox E
Pediatr Blood Cancer; 2012 Nov; 59(5):865-9. PubMed ID: 22847981
[TBL] [Abstract][Full Text] [Related]
43. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
44. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
45. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
Grosso F; Dileo P; Sanfilippo R; Stacchiotti S; Bertulli R; Piovesan C; Jimeno J; D'Incalci M; Gescher A; Casali PG
Eur J Cancer; 2006 Jul; 42(10):1484-90. PubMed ID: 16737808
[TBL] [Abstract][Full Text] [Related]
46. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A
Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175
[TBL] [Abstract][Full Text] [Related]
47. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.
Pardo B; Salazar R; Ciruelos E; Cortés-Funes H; García M; Majem M; Montes A; Cuadra C; Soto-Matos A; Lebedinsky C; Alfaro V; Paz-Ares L
Med Oncol; 2012 Sep; 29(3):2240-50. PubMed ID: 21660618
[TBL] [Abstract][Full Text] [Related]
48. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Hillebrand MJ; Bosch TM; Lopez-Lazaro L; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2007 May; 59(6):825-37. PubMed ID: 16988825
[TBL] [Abstract][Full Text] [Related]
49. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
Grosso F; Sanfilippo R; Virdis E; Piovesan C; Collini P; Dileo P; Morosi C; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Aug; 20(8):1439-44. PubMed ID: 19465423
[TBL] [Abstract][Full Text] [Related]
50. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
51. Experience with second-line trabectedin in daily clinical practice: case studies.
Martín-Broto J; Hindi N; Grignani G; Merlini A; Ibrahim T; Le Cesne A
Future Oncol; 2022 Sep; 18(30s):23-32. PubMed ID: 36200932
[TBL] [Abstract][Full Text] [Related]
52. Trabectedin: Supportive care strategies and safety profile.
Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
[TBL] [Abstract][Full Text] [Related]
53. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
[TBL] [Abstract][Full Text] [Related]
54. A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma.
Buonadonna A; Benson C; Casanova J; Kasper B; López Pousa A; Mazzeo F; Brodowicz T; Penel N
Anticancer Drugs; 2017 Nov; 28(10):1157-1165. PubMed ID: 28926423
[TBL] [Abstract][Full Text] [Related]
55. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.
Grosso F; D'Incalci M
Tumori; 2011; 97(2):256. PubMed ID: 21617728
[No Abstract] [Full Text] [Related]
56. Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas.
Cerdà Serdà P; Terés R; Sebio A; Bagué S; Orellana R; Moreno ME; Riba M; López-Pousa A
Adv Ther; 2022 Apr; 39(4):1596-1610. PubMed ID: 35129790
[TBL] [Abstract][Full Text] [Related]
57. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
Sessa C; Perotti A; Noberasco C; De Braud F; Gallerani E; Cresta S; Zucchetti M; Viganò L; Locatelli A; Jimeno J; Feilchenfeldt JW; D'Incalci M; Capri G; Ielmini N; Gianni L
Eur J Cancer; 2009 May; 45(7):1153-1161. PubMed ID: 19114300
[TBL] [Abstract][Full Text] [Related]
58. Trabectedin.
Chuk MK; Balis FM; Fox E
Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
[No Abstract] [Full Text] [Related]
59. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Garcia-Carbonero R; Supko JG; Maki RG; Manola J; Ryan DP; Harmon D; Puchalski TA; Goss G; Seiden MV; Waxman A; Quigley MT; Lopez T; Sancho MA; Jimeno J; Guzman C; Demetri GD
J Clin Oncol; 2005 Aug; 23(24):5484-92. PubMed ID: 16110008
[TBL] [Abstract][Full Text] [Related]
60. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Le Cesne A; Blay JY; Cupissol D; Italiano A; Delcambre C; Penel N; Isambert N; Chevreau C; Bompas E; Bertucci F; Chaigneau L; Piperno-Neumann S; Salas S; Rios M; Guillemet C; Bay JO; Ray-Coquard I; Haddag L; Bonastre J; Kapso R; Fraslin A; Bouvet N; Mir O; Foulon S
Ann Oncol; 2021 Aug; 32(8):1034-1044. PubMed ID: 33932507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
